hs-cTnI improves prediction of coronary plaque presence and may guide non-invasive coronary atherosclerosis evaluation.Anti-β2GPI IgA predicts progression to extensive/obstructive plaque in patients with non-extensive/non-obstructive disease, especially when hs-cTnI levels are high. The gene discussed is CD79A; the disease is coronary atherosclerosis.